|Home | About | Journals | Submit | Contact Us | Français|
Recent advances in our understanding of the underlying genetic architecture of psychiatric disorders, has blown away “old” diagnostic boundaries defined by currently used diagnostic manuals. The DISC1 gene was originally discovered at the breakpoint of an inherited chromosomal translocation, which segregates with major mental illnesses. Many biological studies have indicated the role of DISC1 in early neurodevelopment and synaptic regulation. Given the additional insight that DISC1 is thought to drive a range of endophenotypes, which underlie major mental conditions, the biology of DISC1 may provide a hint on constructing new diagnostic categories for mental illnesses with more meaningful biological foundation.
Major mental illnesses, such as schizophrenia and mood disorders, remain medical and financial burdens in our society. This is despite revolutions in treatment in the past fifty years with antipsychotic and antidepressant use and the current availability of generic forms of many of these drugs. Statistics from the website of the US research institute, the National Institute for Mental Health (NIMH) highlight this and show that in 2006 alone there was expenditure of nearly $58 billion on mental health in the US (http://www.nimh.nih.gov/statistics/4COST_AM2006.shtml). The often quoted, but unfortunately correct, reason for this predicament is the serendipitous identification of these medications, with no appreciation for the complex underlying pathophysiology. Thus the drugs treat a subset of symptoms but not the core pathology. The product of this approach has been that many disease domains, such as cognitive deficits and negative symptoms in schizophrenia, remain poorly treated1–5. In addition to the severe limitations in efficacy, most of these compounds have substantial side effects6–8 and improved medications are clearly needed. We predict that breakthrough medications for mental illnesses will be developed through an integrated understanding of the etiopathology, genetic underpinnings and altered brain circuitry of these illnesses. Fortunately with the advent of new genetic approaches, such as next generation sequencing9, and a growing toolbox for dissecting brain circuitry10, we are well positioned to deliver on this.
What is abundantly clear is that the major mental illnesses are multi-factorial brain disorders driven by a combination of genetic and environmental susceptibility factors11–13. Recent advances in the understanding of the underlying genetic architecture suggest that “old” diagnostic boundaries defined by currently used diagnostic manuals, such as Diagnostic and Statistical Manual (DSM) and International Classification of Diseases (ICD) may be difficult to reconcile with more biology-based assessments of mental illnesses. For example, shared risk variants between schizophrenia, bipolar disorder, and autism have been reported14–16. The common genetic underpinnings of schizophrenia with diseases which manifest in childhood, such as autism, has further strengthened the view that schizophrenia is likely to include neurodevelopmental etiologies and indicated the importance of looking at early life events for causative factors16,17. A number of key literatures support this notion: epidemiological studies have indicated that adverse events during the prenatal and perinatal periods are important18; premorbid behavioral and neurological signs are prominent in many patients with schizophrenia, whereas brain imaging approaches have identified abnormalities at disease onset17,19. In addition, there are a number of preclinical animal models of schizophrenia that are based on lesions early in development. They only manifest behavioral symptoms post-adolesence, thus mimicking the developmental trajectory of schizophrenia17,20 This delayed onset after puberty also indicates important roles for dynamic changes in adolescent brain maturation, such as loss of glutamatergic synapses (synaptic pruning), maturation of interneurons, dopaminergic neurons, and full development of myelination21. Amongst these possibilities, synaptic changes in adolescence could be very important because synaptic changes have been frequently reported in the pyramidal neurons of the cortex and hippocampus in brains from patients with schizophrenia, and are thought to reflect disease alterations in critical brain circuitry22–24.
Therefore, in studying molecular mechanisms underlying the pathophysiology of schizophrenia and related disorders, a sharp focus on the specific disease neurodevelopmental trajectory, especially in early development and adolescent brain maturation, is vitally important. This significance has been recently summarized in several review articles21,25. As we seek to identify ways and means to understand these complex disorders, the discovery of ‘Disrupted-in-Schizophrenia 1’ (DISC1), a molecule that has crucial roles both early in development and during adolescence, including synapse regulation, has provided an invaluable window onto the disease landscape. In this review, we will describe current thinking on the roles of DISC1 and its network of interacting proteins (interactome) in brain development and the mature brain, and the corresponding influences on phenotypic manifestations relevant to major mental illnesses. We will also critically discuss the therapeutic implications of these findings and the priorities for further study and rationalization across DISC1 biology.
The DISC1 gene was originally identified in a unique Scottish pedigree in which an inherited balanced chromosomal translocation disrupts this gene and segregates with major mental disorders, such as major depression, schizophrenia, and bipolar disorder (The details of the discovery of DISC1 can be seen in BOX 1)26–30. Following the identification of the Scottish pedigree, many groups have examined the genetic association with schizophrenia, bipolar disorder, major depression, autism, and developmental mental disorders31–36. Substantial numbers of studies have reported a modest, but significant, association of the DISC1 locus with these disorders. Indeed, recent reports have identified several ultra-rare DISC1 variants that might be associated with schizophrenia and/or bipolar disorder37,38. However, it should be noted that recent genome-wide association studies (GWAS) have not identified DISC1 as a prominent hit for either schizophrenia or bipolar disorder, and a meta-analysis failed to observe significant association between DISC1 and schizophrenia39–43.
The discovery of the DISC1 pedigree has to be thankful to the UK Medical Research Council and its thorough collection of chromosomal abnormalities in the 1960s and 1970s, and their location in Scotland which enabled multiple generations of the pedigree to be traced27. The pedigree was originally identified and published over forty years ago by Patricia Jacobs and colleagues at the University of Edinburgh as part of a population survey of chromosomal abnormalities28. The original observation of a balanced translocation between chromosomes 1 and 11 [(1;11)(q42.1;q14.3)] was made in an 18-year old boy with adolescent conduct disorder who had been placed in a young offenders institute28. Analysis of his family identified additional members with the translocation and critically, over the next 20 years members of the family were interviewed by psychiatrists Professors David St Clair, Walter Muir and Douglas Blackwood using a standard diagnostic instrument26. Their work confirmed a diagnosis of schizophrenia or other major mental disorder in several family members. In fact all members with a major mental illness carried the translocation. The last detailed clinical report on the family was published in 200130. In 2000, another major breakthrough with the pedigree occurred with Millar and Porteous cloning the gene impacted on chromosome 1. They named the 13 exon gene, with the breakpoint between exons 8 and 9 as ‘Disrupted in Schizophrenia 1’ (DISC1)29. AlthoughDISC1 is the only disrupted transcript within an open reading frame, a transcript occurring on the antisense strand, DISC2, is also disrupted29. The biological consequences of this chromosomal disruption are under debate68–70,173,174 (see Box 2). The scheme is adapted from the previous publication by Blackwood et al30.
There are three major hypotheses at present which address this question. Sawa and Snyder68 initially proposed that this chromosomal abnormality in the Scottish pedigree could lead to a C-terminal truncated DISC1 protein and/or degradation of the protein. Data from cell models indicated that the putative C-terminal truncated protein could act as a dominant-negative78, but the existence of this protein product has not been examined in the brain yet. Furthermore, at least in the lymphoblastoid cell limes from a few subjects with this chromosomal abnormality, the truncated protein was not identified by Western blotting140, Nonetheless, the complexity of DISC1 isoforms and their differences between lymphoblasts and brain, as well as between developing and adult brain, precludes making a strong conclusion here. Most importantly, either a dominant-negative protein or a partial loss of protein leads to an overall loss-of DISC1 function. In addition, the notion that a fusion transcript could form across the breakpoints of both chromosomes 1 and 11 and lead to a fusion protein, which has been shown to be amyloidogenic when overexpressed in cultured cells, has been proposed166.
How can these apparent genetic contradictions be reconciled? Accumulating evidence has been reported in association studies of a genetic link between DISC1 and specific endophenotypes commonly associated with major mental illnesses, including behavioral (anhedonia, frontal lobe-associated memory) electrophysiological (auditory event-related potential) and anatomical (cortical thickness, hippocampal gray matter volume, white matter integrity) characteristics34,44–56. Furthermore, a unique condition of a clinical mixture of schizophrenia and mood disorders, such as schizoaffective disorder, is associated more significantly with the DISC1 locus32,35. Thus, DISC1 may not be a key risk factor for schizophrenia nor other DSM-defined disorders, but does confer a genetic risk at the level of endophenotypes or brain circuitry that underlies many major mental disorders. We can also note that GWAS may require more samples to detect entire repertoires of disease-associated common variants and that most of the genome-wide studies for copy number variants may not fully detect small chromosomal deletions/duplications57,58. Such technical issues may also underlie the failure in identifying DISC1 as a prominent hit in association with schizophrenia.
In parallel with such clinical-genetic studies, efforts to elucidate the biological function of DISC1 have made significant progress in the past decade. DISC1 is highly expressed in the developing brain, and is also expressed in various brain areas including the olfactory bulb, cortex, hippocampus, hypothalamus, cerebellum, and brain stem after birth59. In adulthood, the highest expression of DISC1 is observed in the dentate gyrus of the hippocampus60. DISC1 is expressed not only in neurons (both pyramidal neurons and interneurons)59, but also in glial cells61.
Much of the understanding on DISC1’s biological function comes through an understanding of the biology of DISC1-interacting proteins and the functions of these protein complexes62,63. Though there have been multiple yeast-two hybrid studies reported with DISC164–67, the most comprehensive catalogue of interactions to date was published as the ‘DISC1 interactome’ by Camargo and colleagues63 in 2007 (See Fig. 1 for a modified interactome highlighting relevant proteins discussed in this review). This study comprised iterative yeast-two hybrid screens with DISC1 as the starting protein, followed by screens with a diverse set of DISC1 interactors, representing the most prevalent functional protein classes from the original bioinformatic analysis. The data from this study, together with the early biochemical studies of DISC1, pioneered the concept that DISC1 is likely to be an intracellular scaffold protein with many protein interactors68–70. Since this study, individual interactions have been confirmed in other experimental systems21,71–74. Identification of the specific binding sites for individual interactions has played a major role in deciphering the function of the various DISC1 partnerships, the most important of which are shown in Fig. 2. Studies of the protein interactors of DISC1 have shown that it has at least two major roles in the brain: regulation of key processes in early brain development and synapse formation/maintenance. Such roles are consistent with current hypotheses for the etiopathology of major mental illness and thus provide us a ‘DISC1-shaped’ window to view these diseases.
Using yeast two-hybrid screening, multiple labs independently determined that DISC1 interacts with a class of proteins that interact with microtubules and associated complexes (Fig. 1). These proteins include NDEL1, NDE1, LIS1, 14-3-3, dynactin, MIPT3, and MAP1A64,66,75–77. The interactions of DISC1 with these microtubule-related proteins have also been confirmed biochemically64,66,75,76. Immunofluorescent cell staining and biochemical studies have indicated that DISC1 is located to the centrosome, which is the microtubule-organizing center, and also associates with microtubules themselves64,76,78. A C-terminal truncated form of DISC1 (amino acids 1-598), that could be generated by the chromosomal abnormality identified in the original Scottish pedigree functions as a dominant-negative, blocking proper accumulation of DISC1 (A discussion on possible pathological mechanisms due to this chromosomal abnormality is introduced in BOX 2), NDEL1, and their dynein associated proteins to the centrosome and disturbing microtubular dynamics78. It is now appreciated that regulation of microtubules is critical for key neurodevelopmental processes such as neuronal migration. What is the major role for DISC1 in association with the microtuble-centrosomal network in the brain? Studies of Miller-Dieker lissencephaly syndrome, a human developmental brain disorder caused by neuronal migration defects resulting in abnormal layering of the cerebral cortex, have shown that LIS1, a DISC-1 interacting protein, is causal for the disease79. Furthermore, RNAi knockdown of LIS1 and NDEL1 in developing mouse brains impairs centrosome-associated microtubular dynamics and leads to defects of neuronal migration in the developing cortex80. These results together with the finding that DISC1 expression is higher in the developing cortex59,66 led to an intriguing hypothesis that DISC1 may be implicated in neurodevelopmental processes, in particular neuronal migration.
Radial migration of cortical neurons is an important stage of cortical development and is known to involve microtuble-centrosomal machinery81. A key role for DISC1 in neuronal migration was illustrated by DISC1 knockdown using in utero introduction of short-hairpin RNA (shRNA) at embryonic day 14.5 (E14.5). This elicited robust defects in radial migration in the cortex78 similar to those produced by knockdown of NDEL1 or LIS180,81. Consistent with this finding, expression of the C-terminal truncated dominant-negative DISC1 (described DN-DISC1 in the following sections) results in a similar delay in neuronal migration78. The similarity of phenotypes elicited in these experiments suggests a possible disturbance of the motor-microtubule-centrosome machinery. Indeed, a number of molecular components of this machinery have since been shown to be novel protein interactors of DISC1. These proteins include Bardet-Biedl Syndrome (BBS) proteins, such as BBS1 and BBS4, and Pericentriolar Material 1(PCM1) (Fig. 1). In the developing cortex, cooperative action of DISC1 and BBS4 is required for accumulation of PCM1 to the centrosome and proper neuronal migration82. It should also be noted that the gene coding for PCM1 by itself is a promising candidate for schizophrenia82–84. Furthermore, two nonsynonymous genetic variants, i.e. mutation leads to a change in amino-acid sequence, in the DISC1 locus (S704C, L607F) affect centrosomal PCM1 localization85,86. Taken together, these findings indicate that DISC1 is likely to be an intrinsic factor that regulates migration in the developing cortex (Fig. 3).
In cortical development, proper control of progenitor cell proliferation is another key element that operates in parallel to postmitotic neural migration. Following the initial discovery of a role for DISC1 in neural migration, the Tsai lab87 explored a role for DISC1 in progenitor cell proliferation in the developing cortex (Fig. 3). Reduction of DISC1 protein levels by shRNA at E13 results in substantial impairment of cortical progenitor proliferation and reduction of cells in the ventricular and subventricular zones. A key underlying mechanism was shown to be the loss the ability of DISC1 to interact with and inhibit glycogen synthase kinase-3β (GSK3β) (Fig. 1), which in turn phosphorylates β-catenin and mediates its degradation87. β-catenin is an important component of canonical Wnt signaling, which controls progenitor cell proliferation, and implicates DISC1 as a regulator of this pathway. Consistent with this observation, a transgenic mouse that exogenously expressed a portion of the DISC1 genomic locus within a ‘Bacterial Artificial Chromosome (BAC)’, that mimics the chromosomal 1 truncation found in the Scottish pedigree (BAC-DN), exhibits reduced neural proliferation during cortical neurogenesis88 (Table 1).
The DISC1 ‘interactome’ has identified other DISC1-interacting proteins that are involved in progenitor proliferation and neural migration. For example, ‘Coiled-coil protein Associated with Myosin II and DISC1’ (CAMDI) plays a role in neuronal migration and interacts preferentially with phospho-myosin II and induces an accumulation of phosphomyosin II at the centrosome in a DISC1-dependent manner89. Indeed, a single nucleotide polymorphism in the Camdi gene (R828W) leads to a reduction of protein binding between CAMDI and phosphomyosin II, and mice overexpressing R828W in neurons exhibit impaired radial migration. Furthermore, another recently identified DISC1 regulator and interacting protein is DIX domain containing-1 (Dixdc1), the third mammalian gene discovered to contain a Disheveled-Axin (DIX) domain90 (Fig. 1). Dixdc1 regulates dual roles for DISC1 in embryonic neural progenitor proliferation and neuronal migration. Dixdc1 functionally interacts with DISC1 to regulate neural progenitor proliferation by co-modulating Wnt-GSK3β-β-catenin signaling. In contrast, phosphorylation of Dixdc1 by cyclin-dependent kinase 5 (Cdk5) facilitates DISC1-NDEL1 interaction and in turn neuronal migration.
Although many molecules have been shown to regulate the processes of progenitor cell proliferation and neuronal migration, the molecular mechanisms responsible for the transition from neuronal proliferation to neuronal migration are largely unknown. A mass spectrometry effort to identify posttranslational modifications which might be critical for this transition identified a specific phosphorylation event at serine-710 in mouse DISC1 which could be a critical marker for this process91. GSK3β preferentially binds to DISC1 when it is non-phosphorylated at this site (S710-DISC1), whereas BBS1 and BBS4 interact preferentially with DISC1 when phosphorylated at S710. Thus, through an increase in phosphorylation of DISC1 at S710, which occurs at embryonic stage E13-15, DISC1/BBS binding recruits DISC1 away from a GSK3β-regulated Wnt/β-catenin activity, and contributes to the switch from neuronal progenitor proliferation to neuronal migration. In summary, accumulating evidence consistently uncovers dual roles for DISC1 in corticogenesis, from regulation of progenitor proliferation to mediation of postmitotic neural migration91. The phosphorylation of residue S710 on DISC1 is a key regulator to coordinate these two roles91 (Fig. 3).
It is very important to note that the data discussed above, which suggests a key role for DISC1 in neuronal proliferation and migration, has used principally RNAi-based approaches which reduce levels of a particular protein in order to study its biological effect. Looking at alternative approaches, the systematic histological analysis of mice with point mutations in the DISC1 gene (Q31L and L100P)92 has shown a reduction in neuron number and altered neuron distribution in the cerebral cortex, compared to wild-type littermates. Although these phenotypes are suggestive of a role for DISC1 in neurogenesis and neuron migration (Table 1), the phenotypes in the mouse models are more modest than those in the models mediated by RNAi. This would suggest the existence of parallel mechanism(s) that may compensate for the DISC1-mediated disturbance and mask the resultant phenotypes in the mutant mice.
DISC1 is highly expressed in the hippocampus, especially in the dentate gyrus where neurogenesis takes place, not only in early development but also in adulthood60. To address roles for DISC1 in the hippocampus, most studies have also utilized RNAi methods. Downregulation of DISC1 in adult dentate gyrus leads to accelerated neuronal integration, resulting in aberrant morphological development and mispositioning of new dentate granule cells in a cell-autonomous fashion93. Newborn neurons with reduced DISC1 levels exhibit enhanced excitability and accelerated dendritic development and synapse formation93. Considering that the same group observed delayed neuronal migration in the developing cortex with the same shRNA to DISC193, this phenotype is likely to be unique to adult dentate gyrus. This unique phenotype seems to be mediated by AKT and the DISC1 interacting protein KIAA1212/Girdin94 (Fig. 1). Interestingly, knockdown of Girdin also leads to overextended migration and mispositioning of dentate granule neurons95. Knockdown of DISC1 in newborn granule cells in adulthood also leads to defects in axonal targeting and development of synaptic outputs96. Influence of DISC1 on newborn neurons seems to be developmental stage dependent: downregulation of DISC1 hinders the migration of dentate gyrus granule cells during early development, contrasting to its influences in adult dentate gyrus97. In CA1 of the developing hippocampus, knockdown of DISC1 at E15 leads to clearly disturbed migration at postnatal day 3 (P3)97, although more subtle alteration does appear at P298. Some of these results obtained with DISC1 RNAi have been consistently observed in other DISC1 mouse models. An example is data from a mouse model containing a 25-base deletion in exon 6 of DISC1, derived from the 129 mouse strain, and a premature polyadenylation site in intron 8 (described as the deletion model in the following sections), which results in loss of some DISC1 isoforms, dendritic misorientation, and impaired growth phenotypes in newborn neurons of the adult dentate gyrus99 (Table 1). An intraperitoneal injection of the NMDA-type glutamate receptor antagonist memantine into adult male mice also leads to a decrease in expression of DISC1 and overextended migration of newborn neurons in the dentate gyrus, which is rescued by exogenous expression of DISC1100. Decrease in DISC1 expression in the adult dentate gyrus is also reported in long-term kindled rats101. Together, these results indicate that DISC1 also plays roles in neurodevelopmental processes in the hippocampus, but its influences on phenotypes in adult dentate gyrus is unique compared to those in many other brain areas.
Deficits in dendritic spines and glutamatergic neurotransmission are shared across a number of mental illnesses to which DISC1 has been genetically associated102. Dendritic spines contain the postsynaptic compartment of the majority of excitatory synapses in the brain, and their morphology has been inextricably linked to neuronal activation and synaptic plasticity103–108. Recent reports make a compelling case for DISC1 localization and function at the postsynaptic density (PSD) and a role in the development and maintenance of synapses.
There is now evidence from electron microscopy, immunocytochemistry, and biochemical analyses that DISC1 is found at synapses. An initial study with human post-mortem frontal and parietal cortex samples showed that a pool of DISC1 is localized in the synapse109. Approximately 40% of synapses, especially excitatory synapses, were labeled for DISC1. It is worthwhile noting that there was staining of inhibitory symmetrical synapses and that this is an area worth re-visiting in future studies. A similar PSD-localization was also recently shown in rat cortical and hippocampal cultures as well as mouse striatum110–112. Supporting the imaging studies, DISC1 has been shown by classical subcellular fractionation approaches to be enriched in the post-synaptic density fraction110,111,113.
In cortical neuron culture, knockdown of DISC1 with shRNA has been shown to regulate spine size, spine number, surface levels of the AMPA-type glutamate receptor subunit GluR1, and the frequency of miniature excitatory post-synaptic currents (mEPSCs)110. The delivery of GluR1 to the plasma membrane, probably to extra-synaptic domains, and then subsequent insertion into synaptic sites is crucial for increasing spine size, morphology and synapse strength114,115. Consistent with these observations in neuronal culture, many mouse models with DISC1 also display synaptic pathology. For example, the Q31L and L100P mutant mice show reduced spine density on pyramidal neurons in layers III and V of the frontal cortex and CA1 neurons in hippocampus92 (Table 1). Another mouse model (the so-called deletion model; see previous section for details) shows decreases in synaptic spines and associated abnormalties in the dentate gyrus99 (Table 1). A knockdown model of the NMDA-type glutamate receptor subunit NR1, which has been previously characterized to exhibit behavioral deficits relevant to mental disorders116, shows reduced levels of DISC1 and a key DISC1 interactor 14-3-3 epsilon at synapses and also shows spine shrinkage in the striatum suggesting that there is an intimate relationship between the activity of NMDA receptors and either DISC1 stability or perhaps subcellular targeting112. By contrast, knockdown of DISC1 in the dentate gyrus by shRNA in adult C57BL/6 mice reportedly leads to accelerated formation of dendritic spines in newborn neurons that have both glutamatergic and GABAergic synapses, as measured functionally by electrophysiology93. These studies provided the impetus to understand the function of DISC1 in regulating spine form and function.
The ‘DISC1 interactome’ is a protein-protein interaction study based on iterative yeast-two hybrid data screens with DISC1 as the core ‘starter’ protein62,63. The findings from these studies predicted that DISC1 would be a key synaptic player, as the DISC1 protein environment was enriched in proteins found at the synapse and involved in NMDA receptor-dependent signaling63 (Fig. 4).
Amongst DISC1 interacting partners known to localize to the synapse, Kalirin-7 (Kal-7) was a attractive candidate to explain the effects of DISC1 knock down in cultured neurons (Fig. 1). In autopsied brain, Kal-7 mRNA (Duo in humans) is reduced in patients with schizophrenia117, and a GWAS in the Japanese population showed association at the KALRN locus (including Kal-7 and other isoforms) on 3q21.2 with schizophrenia118,119. In addition, re-sequencing of KALRN exons identified a number of rare mutations, two of which have been shown to be significantly associated with schizophrenia119. Furthermore, Kalrn knockout mice have deficits in working memory, social interaction, and prepulse inhibition, all of which are relevant as endophenotypes of schizophrenia and related disorders120. Kal-7, the most abundant isoform of the Kalrn genes found in the brain, is a Rac1-GTP exchange factor (GEF) that activates the small GTPase Rac1 and has been shown to be localized to the PSD121,122. A growing body of literature has shown that Kal-7 is crucial for spine form and function in a number of different contexts122. In immature hippocampal neurons ephrinB/EphB signaling regulates spine maturation through Kal-7 and activation of Rac1 and PAK1123. Activity-dependent spine morphogenesis in mature neurons has also implicated Kal-7, for example NMDA-receptor dependent activation of CaMKII results in phosphorylation of Kal-7 which increases its GEF activity and subsequent increases spine size and synaptic strength through increasing synaptic levels of GluR1124. Kal-7 has also been shown to be regulated in cortical interneurons by Neuregulin-1 (NRG1)/ErbB4 signaling to control dendritic arborization125,126. The interaction of Kal-7 with DISC1 was shown originally in three independent yeast two-hybrid screens63,67,110, and confirmed by standard biochemical techniques as part of a trimolecular complex with PSD-95110. At the baseline condition, DISC1 enhances binding of Kal-7 and PSD95, blocking the access of Kal-7 to Rac1. Once the NMDA receptor is activated, these protein interactions are weakened, allowing the free access of Kal-7 to Rac1, leading to the activation of Rac1110. Although Rac1 activity is crucial for synapse formation and maintenance, excess activation of Rac1 leads to synaptic shrinkage. Thus, regulation of Kal-7’s access to Rac1 by DISC1 in an activity-dependent (e.g., NMDA receptor activation-dependent) fashion is crucial for the proper maintenance of the synaptic spine110. Of note, a recent paper suggests that DISC1 can mediate axon guidance via regulating TRIO, another GEF for Rac1127.
Understanding the role of DISC1 in maintaining synapse form and function further has come via studies of a kinase known as Traf- and nck-interacting kinase (TNIK), a member of the Ste20 kinase family111. Specifically TNIK is a Germinal Center Kinase Type IV kinase (GCK type IV) and is characterized by a conserved N-terminal kinase domain and a C-terminal citron-homology domain (CNH), and a less well conserved intermediate domain128. Initial functions ascribed to TNIK are activation of the c-Jun N-terminal kinase (JNK) pathway, and regulation of the actin cytoskeleton by disruption of filamentous actin (F-actin), in a kinase activity-dependent fashion129. Until recently though, there was little known about the function of TNIK in the brain. Interest emerged from unbiased proteomic profiling studies of PSDs of the mouse and rat, where TNIK was identified by mass-spectrometry methods130,131. Initial links to schizophrenia have emerged from GWAS studies that implicated TNIK as a risk factor for schizophrenia and as a determinant of prefrontal cortical function in schizophrenics42,132. The DISC1 link to TNIK has origins in the ‘DISC1 interactome’ study, where TNIK was clearly one of the more heavily connected partners63 (Fig. 1). TNIK and DISC1 are found colocalized in dendritic spines in cultured primary neurons, which was confirmed by electron microscopy111. DISC1 binds specifically to the kinase domain of TNIK, which clearly implicated DISC1 as a regulator of TNIK kinase activity, which was subsequently experimentally confirmed111. Mapping of the binding site of TNIK on DISC1 identified a crucial thirteen amino-acid long sequence between residues 335–347. It is worth noting that a rare SNP, R338Q, linked to bipolar disorder is found within this binding site38 (Fig. 2). The binding domain peptide was serendipitously characterized as a potent inhibitor of TNIK kinase activity111. Inhibition of TNIK function, by either this peptide or a shRNA knockdown approach, leads to the selective degradation of a number of key postsynaptic proteins including GluR1 and the scaffold protein PSD-95, a loss of GluR1 from the membrane surface and decreases in the amplitude and frequency of mEPSCs111. A second report has shown similar cellular phenotypes after knockdown of the related kinase Misshapen like kinase (MINK)133. This implicates DISC1 and TNIK in the maintenance of synapse structure, probably through both proteasomal and lysosomal degradation pathways. Recently the role of protein degradation and the ‘ubiquitin-proteasome system’ (UPS) in particular, in regulating synaptic plasticity and behavior, has become more widely appreciated134. Co-administering the TNIK peptide inhibitor with either lysosome or proteasome inhibitors shows a clear blockade of protein degradation seen with the TNIK peptide inhibitor alone, in a manner consistent with our current knowledge about routes of degradation for the specific proteins involved134–136. To understand how TNIK regulates protein degradation the spot-light has fallen on Neuronal precursor cell-expressed developmentally downregulated protein 4-1 (Nedd4-1), a member of the Homologous to E6-associated protein C-terminus (HECT) class of E3 ubiquitin ligases134,137. Kawabe and co-workers138 recently showed that Nedd4-1 is critical for dendrite extension and arborization and for normal synapse formation, and identified TNIK as a specific Nedd4-1 binding partner. In addition, Nedd4-1 has been shown to directly interact with, and ubiquitinate GluR1 and drive its endocytosis and subsequent lysosomal degradation in mature hippocampal cultures139. In our own studies either knockdown of TNIK or inhibition of TNIK kinase activity, which both led to a decrease in GluR1 protein levels, could lead to the elevated activity of Nedd4-1, increased ubiquitination of GluR1 and subsequent degradation. It is possible that TNIK might regulate Nedd4-1 activity either through a scaffolding function or more directly through phosphorylation. Furthermore this suggests that changes in DISC1 function which impact TNIK activity, could regulate synapse form and function through regulation of protein degradative pathways.
In addition to Kal-7 and TNIK, there are other DISC1-interacting proteins that are likely to play a role in the synapse, including GSK3 and phosphodiesterase-4 (PDE4)87,140,141 (Fig. 1). The relationship between DISC1 and GSK3 has clearly been highlighted in terms of regulating neuronal precursor proliferation and differentiation. To date there have been no specific studies of this complex in the mature brain or at the synapse, but it is worth noting that GSK3 has been shown to play roles in both LTP and LTD142. PDE4 has been localized to synapses and specifically shown to co-localize with DISC1 at PSDs in the pre-frontal cortex (PFC) of non-human primates143. There are preliminary suggestions that DISC1-localized PDE4 is essential for regulating cAMP levels in the PFC and acts as a buffer against stress-induced PFC dysfunction143. Finally, a recent report indicates that synaptic modulators Nrxn1 and Nrxn3 are disregulated in L100P-DISC1 mice144. The challenge now is to understand how DISC1 regulates multiple pathways at the synapse over the course of nervous system development. Are the different functional modules independent or dependent on each other? Are they found in different cell types and synapses? And how does all of this change with ageing, key developmental milestones and of course disease?
There are eight distinct animal models for DISC1 already published (Table 1). Surprisingly there is not a traditional knockout mouse amongst them, which may be in part due to the complexities of DISC1 isoforms, which are still very poorly understood (see below). As described above, several studies have addressed whether anatomical and histological defects exist in these models and shown alterations in the cortex and hippocampus72,145–147. We have already discussed the significant but modest phenotypes in models of germ-line genomic lesions, which is in part because DISC1 pathways are likely to be regulated by a number of redundant mechanisms. Notably, all DISC1 animal models show a substantially overlapping behavioral profile. There are some differences seen across models, but at this stage it is too early to understand the significance of any differences until the models are compared alongside each other in the same laboratory. The different DISC1 mouse models have been recently comprehensively reviewed148.
As shown in Table 1, frontal deficits characterized by impairments in working memory [measured by a Delayed Non-Matching to Place (DNMTP) task] and latent inhibition are evident in all the DISC1 models thus far tested, whereas spatial learning and memory are not disturbed99,113,149–152. In addition to these frontal deficits, most DISC1 animal models show deficits in prepulse inhibition, a measure of sensory-motor gating and another representative endophenotype relevant to schizophrenia113,150,153. However, as expected from the mixed clinical phenotype of the DISC1 Scottish pedigree and other genetic association studies30,41, behavioral changes are not limited to endophenotypes of schizophrenia. For example, many DISC1 models show increased immobility time in the forced swim test, a traditional but well-accepted behavioral assay to test the efficacy of antidepressants154.
The presence of multiple different clinical diagnoses in a single pedigree, as seen with the Scottish DISC1 family, is not uncommon but typical of families with a high mental-illness ‘load’ 26,155. What could be the underlying mechanism(s) that account for family members with different psychiatric diagnoses elicited by the same genetic mutation? In the case of DISC1 it is possible to hypothesize that dysregulation of different DISC1 interacting partners may contribute to the different diagnoses seen. This is purely hypothetical at this moment but is a very attractive model to consider. Because major mental illnesses are believed to occur via a combination of genetic and environmental factors, one possible mechanism might be modification by environmental factor(s). To address this hypothesis from a DISC1-centric viewpoint, several publications have addressed how environmental factors affect behavioral phenotypes of DISC1 animal models. Ibi and colleagues156 administered polyriboinosinic-polyribocytidylic acid (polyI:C), which mimics innate immune responses elicited by viral infection early in development, to a transgenic model expressing the putative dominant-negative C-terminal truncated human DISC1 under regulation by the CaMKII promoter150 (constitutive CaMK-DN mice described in Table 1). They reported that this environmental stressor, which mimics an early environmental insult linked with schizophrenia, administered between P2 and P6, augments a range of behavioral and anatomical phenotypes, including a decreased immunoreactivity in parvalbumin-positive interneurons in the medial prefrontal cortex (Table 1). More recently, it has been reported that in another transgenic model expressing the dominant-negative human DISC1, prenatal immune activation with poly I:C to pregnant dams at gestational day 9 can also augment, and in some cases reveal, a particular phenotype157. In this experimental paradigm, anxiety and depression-like responses and social behavior deficits become prominent in the presence of this prenatal environmental stressor (Table 1). These results suggest that hereditary DISC1 animal models may be good templates to study gene--environment interactions for major mental illnesses, which can be used to address questions of whether and how environmental stressors augment intrinsic abnormalities due to genetic factors and modify final phenotypic manifestations.
In addition to behavioral abnormalities, neurochemical and signaling cascades that underlie such behaviors are consistently altered in DISC1 animal models (Table 1). Prominent changes in dopaminergic neurotransmission have been reported153,158,159. A model based on transient knockdown of DISC1 in cells of the pyramidal neuron lineage in the developing cortex via in utero shRNA transfer at E14, driving knockdown for 1–2 weeks, shows deficits in several behavioral domains only in adulthood. These include working memory, prepulse inhibition, and methamphetamine-induced locomotion153. Consistent with these behavioral changes, insufficient maturation of mesocortical dopaminergic projections and an augmented surge of dopamine release in the nucleus accumbens upon amphetamine challenge were reported. Interestingly, these effects were observed only after puberty153, which parallels the initial etiology of human schizophrenia, which tends to emerge in young adulthood. Therefore, this model mimics a developmental trajectory that is characteristic to schizophrenia and is distinct from autism and other neurodevelopmental disorders25. In a CaMK-DN model, a significant decrease of tissue dopamine (DA) and 3,4 dihydroxy-phenylacetic acid (DOPAC) in cortex is observed159. Of note, decreased immunoreactivity in parvalbumin-positive interneurons, a cell-type known to be decreased in the frontal cortex of schizophrenic patients and thought to contribute to the establishment of cognitive deficits, is observed in both these two models153,157,159. This might be significant, considering that a bi-directional relationship between dopaminergic defects and interneuron dysfunction underlying behavioral defects is a currently hotly debated topic in schizophrenia research160. Furthermore, in L100P-DISC1 mice, a two-fold increase in the proportion of striatal D2 dopamine receptors in the high affinity state is observed158. The effects on intracellular signaling pathways that are known to be downstream of dopamine receptors, such as cyclic AMP signaling and GSK-3, have also been addressed in DISC1 models161,162. In the Q31L-DISC1 mice, a decrease in activity of phosphodiesterase-4 (PDE4) and an increased sensitivity to a GSK-3 inhibitor, TDZD-8, are observed161. In L100P-DISC1 mice, the protein interaction of DISC1 with GSK-3 is reduced, and both pharmacological and genetic inactivation of GSK3 ameliorate prepulse inhibition, latent inhibition and locomotor activity deficits161. Furthermore, combined treatment of L100P-DISC1 mice with the PDE4 inhibitor rolipram and the GSK3 inhibitor TDZD-8 at sub-threshold doses can correct defects in prepulse inhibition and hyperactivity, possibly suggesting synergistic interactions between PDE4, GSK3, and DISC1161. Many reports with DISC1 animal models in the last several years have reinforced the notion that DISC1 is implicated in higher brain functions, such as cognition and emotion. Although care needs to be taken when extrapolating these preclinical observations to a role for DISC1 in human mental disorders, it is clear that disturbance of DISC1 in mouse models impacts endophenotypes that are relevant to schizophrenia and related disorders.
There are a number of major areas of particular importance for future studies of DISC1 animal models. As described above, there are a number of consistent behavioral changes observed across the different DISC1 mouse models but one of the biggest gaps in this area though is a neuronal circuit-based discussion to explain the different phenotypes. To date there have been no reports of optogenetic approaches applied to DISC1 biology to understand the specific cells which are relevant to its function. There are also no conditional knock-out mice available to understand the selective loss of DISC1 in distinct circuits. These scenarios are also compounded.by no publications showing the electrophysiological properties of cell or networks from these mice. It is possible though to make some suggestions from observations made at the cellular level in relation to the behavioral effects seen. For example, as described above, more than one DISC1 model shows a consistent decrease in parvalbumin immunoreactivity in the interneurons of the frontal cortex. This decrease is known to reflect hypofunction of specific types of interneurons that regulate cortical synchrony, being represented by gamma oscillations, and in turn underlie working memory163. Furthermore, working memory is also properly maintained by coherence of the hippocampus and prefrontal cortex164, both of which are particularly impaired in many DISC1 animal models (Table 1). It is now very important to address the functional connectivity of the prefrontal cortex and hippocampus experimentally. In the future, it will be critical to conduct behavioral studies alongside in vivo electrophysiology experiments.
Furthermore, as described, DISC1 is a multifunctional protein with expression not only in neuronal cells but also in glial cells61 and in cells of a neuronal lineage, roles for DISC1 are likely to differ in a developmental and brain-region dependent manner. To address the influences of DISC1 in each context on circuitry and behavior, animal models that allow precise control of DISC1 expression in a spatially and temporally specific manner, most likely through the generation of conditional knockout mice, are not available yet but are eagerly awaited by those working in this area. Second, animal models that can address epistatic effects of DISC1 and its interactors need to be studied in the context of mental disorders. Cross-breeding of DISC1 model mice with other transgenic lines, and introduction of viral vectors that modulate expression of DISC1 interactors in DISC1 models may be realistic approaches. Alternately, models with in utero gene transfer, which allow the introduction of multiple expression/knockdown constructs153,165, may also be useful. Finally, as described, the study of gene-environment interactions by using DISC1 animal models will be important.
In addition to roles for DISC1 in early brain development and synapse formation and maintenance, there are several intriguing reports that shed light on other functions of DISC1. The characterization of these functions has to be treated as preliminary as in general it has been limited to in vitro assays.
An increasing number of studies are exploring possible links between schizophrenia susceptibility factors both at genetic and functional levels. Wood and colleagues166 demonstrated that the knockdown of disc1 by morpholino antisense methods in zebrafish disturbs oligodendrocyte development. It does so by promoting specification of olig2-positive cells in the hindbrain and other brain regions, which resembles the phenotypes seen with knockdown of neuregulin1 (nrg1), a major susceptibility gene for schizophrenia in humans. Consistent with this initial suggestion, induction of an isoform of DISC1 (a 130 kDa isoform) by NRG1 is observed in primary cortical neuron cultures from rodents61. Consistently, downregulation of DISC1 is observed in embryos of nrg1 knockout mice. Furthermore, in β-site amyloid precursor protein cleaving enzyme-1 (BACE1) knockout mice where the active form of NRG1 is no longer generated, similar downregulation of DISC1 is seen61. Induction of DISC1 by NRG1 is blocked by LY294002, a small molecule inhibitor of PI3K, indicating that this cascade is possibly mediated through AKT1. As described in a section above, DISC1 and AKT are functionally connected via KIAA1212/Girdin94,95. Demonstration of links amongst these schizophrenia susceptibility factors, such as DISC1, NRG1, AKT, and Olig2 may further support a notion of convergent molecular pathways underlying the pathology of the disease.
In addition, a possible protein interaction of DISC1 with Dysbindin (the protein encoded by DTNBP1) is intriguing167. Dysbindin is another promising risk factor for schizophrenia and linked to the cognitive deficits seen in the disease168. At the cellular level it has been recently linked to synapse function through both pre- and post-synaptic activities169,170. DISC1 and Dysbindin have been suggested to share a number of common binding partners from the results of the DISC1 interactome63,167. A recent report indicates that Dysbindin binds to DISC1 aggregates in recombinant systems and co-fractionates with DISC1 high-molecular weight aggregates from human postmortem tissue167. This study has two major implications: first, it further confirms a promising working hypothesis on the convergent pathways in mental illnesses; second, this is consistent with a previous study that DISC1 protein is found within insoluble fractions in brains from patients with schizophrenia and affective disorders, but not normal controls171. This observation supports an intriguing hypothesis that a mechanism associated with protein misfolding and aggregate formation may underlie the pathology of schizophrenia, like those for neurodegenerative disorders, such as Alzheimer’s disease and Huntington’s disease. Interestingly, a protein interaction of DISC1 and Huntingtin, the disease protein for Huntington’s disease, has been suggested by the existence of many common binding proteins and subsequent bioinformatic analyses63,66,67,78,172. Direct validation of this protein interaction at the experimental level is awaited. Also of interest is that in the original Scottish pedigree there are reports that a fusion transcript could form across the breakpoint on chromosome 1 (encodes N-terminal 1-598 amino acids of DISC1) and the breakpoint on chromosome 11. Critically this transcript can form a protein, which has been shown to be amyloidogenic when overexpressed in cultured cells173,174. This misfolded DISC1 fusion protein might play a pathological role in patients of the Scottish pedigree. Taken together, although it is still hypothetical, a role for misfolded DISC1 in the pathology of schizophrenia and related disorders may be an attractive concept, worthy of future investigation and clarification.
The story around DISC1 and mitochondria is growing. DISC1 has been found in mitochondria using immunocytochemical techniques in cultured primary neurons and also electron microscopy in rat hippocampus and mouse striatum66,75,175. The brain demands a large percentage of the body energy output due to the needs of synaptic transmission and action potential generation176,177. Mitochondria are localized to synapses to provide the required ATP for high fidelity synaptic neurotransmission and also to act as a calcium buffer. Synaptic activity, in a NMDA receptor-dependent manner, has been shown to regulate mitochondrial localization to dendritic spines through tethering to specific proteins176. Recently it was shown that knockdown or overexpression of DISC1 regulates the trafficking of mitochondria in cultured hippocampal neurons178. DISC1 has been shown to bind to a range of mitochondrial proteins that could possibly play a role in these events and perhaps in targeting mitochondria to the synapse. For example ‘Fasciculation and elongation factor 1’ (FEZ1) has been shown to bind DISC1 and together play a role in neuronal outgrowth65, while independently FEZ1 has a role in regulating mitochondrial motility179. The inner mitochondrial membrane protein Mitofillin has also been shown to bind DISC1180. Decreases in DISC1 or Mitofillin were both shown to decrease NADH dehydrogenase and mitochondrial monoamine activities and to cause abnormal mitochondrial calcium dynamics. These effects could explain the effects on the trafficking of mitochondria mentioned previously178. Intriguingly, DISC1 stabilizes Mitofillin and prevent its degradation by the proteasome, explaining the phenocopies of effects after knocking down either protein. It will of course be interesting to see what is responsible for the degradation here and whether Nedd4-1 has a role. Together these partnerships suggest that DISC1 could play an important role in mitochondrial activity and possibly its synaptic localization in neurons.
A pool of DISC1 is enriched in the nucleus, in particular within the promyelocytic leukemia (PML) nuclear body, and is likely to regulate gene transcription181. A yeast two-hybrid screen, followed by biochemical confirmation, indicates that DISC1 binds with activating transcription factor 4 (ATF4) [aka, cAMP-response element binding protein-2 (CREB2)] and ATF564. In cultured cells, such as HeLa cells, DISC1 interacts with ATF4/CREB2 and a co-repressor N-CoR, modulating CRE-mediated gene transcription181. DISC1-dependent transcriptional repression is also reported in zebrafish cranial neural crest for the foxd3 and sox10 genes182. Furthermore, DISC1 reportedly regulates expression of N-cadherin and β1-integrin in PC12 cells183. Functional roles for nuclear DISC1 in the mammalian brain remain to be elucidated. So far, a role of nuclear DISC1 in sleep homeostasis in drosophila melanogaster and in neural crest migration and differentiation in zebrafish has been suggested181,182. In a study with human autopsied brains (focus on orbitofrontal cortices), an altered distribution of a 75 kDa isoform of DISC1 to the nucleus, is observed in association with psychosis and substance and alcohol abuse184.
Analysis of a role for DISC1 in neurite outgrowth, mainly within PC12 cells, has suggested several novel functions for DISC1. PC12 cells stably overexpressing wild-type DISC1 show an increase in neurite outgrowth65, whereas knockdown of DISC1 via RNAi or expression of a dominant-negative C-terminal truncated DISC1 leads to a decrease in outgrowth66,78. The protein interaction of DISC1 with NDEL1 is required this effect185. However, the fact that an endo-oligopeptidase activity of NDEL1 is also required for neurite outgrowth can be inhibited by its interaction with DISC1186 suggests that this interaction is likely complex and has dual roles in this process. In addition to the DISC1-NDEL1 interaction, binding of DISC1 with FEZ1 also reportedly participates in this process65. Furthermore, a novel protein DISC1-Binding Zinc finger protein (DBZ) can modulate DISC1-dependent neurite outgrowth, which may be influenced by exogenous Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)187. Although all of these proposed mechanisms are interesting, whether they occur in the brain and which specific circuits they regulate, requires validation.
Over the past ten years, since the isolation and cloning of the DISC1 gene, many studies of its corresponding protein have been conducted. Almost all support the notion that this is an intracellular anchoring protein that has many protein interactors, and is found in multiple subcellular domains. Many of the key interacting proteins are also genetic risk factors for schizophrenia and other mental illnesses, suggesting that DISC1 is a hub for several pathways underlying mental disorders. Nonetheless, several key questions remain to be answered.
First, the molecular complexity of DISC1, especially its protein isoforms, is not well understood. Initial studies following the identification of the gene suggested that DISC1 has four isoforms (L, Lv, S, Es)188. However, the multiple specific protein bands seen by Western blotting experiments, with a multitude of anti-DISC1 antibodies, were not as predicted from the mRNA experiments. This enigma was further amplified by observed DISC1 immunoreactivity by Western blotting of brain from the 129 strain of the mouse, in which a 25-base deletion in coding exon 6 of the Disc1 gene exists. DISC1 immunoreactivity obtained from brain extracts of 129 and C57BL/6 strains (no 25-base deletion) are not distinguishable with many antibodies against DISC1189, including very popular commercial reagents that have been used in key studies of DISC1 suggesting careful characterization of antisera and mouse models, with a range of control experiments and antisera respectively is absolutely required (see below for details) 87,90,93,96,101,190–192. Accordingly, the Gogos/Karayiorgou lab99 has suggested caution in using antibodies against DISC1 and in characterizing RNAi experiments, which is strongly dependent on Western blotting with these same antibodies. As many findings on DISC1 have come from experiments with RNAi78,87,90,91,93,96,98,110,111,153,158,193,194, this experimental issue should not to be ignored. However, the following recently published studies are likely to provide a solution to move this debate along and indicate future strategies that should be taken in DISC1 research: the Weinberger lab195 has recently reported that DISC1 has many isoforms (many more than those classically reported). Consistent with this report, DISC1 RNAi-s that have been used for many studies have functional effects in both 129 and C57BL/6 strains, suggesting that 129 strain maintains functional DISC1 isoforms165. Although the publication from the Weinberger lab supports the concept that there are still many unknown isoforms of DISC1, this paper even does not fully account for all the mysterious patterns of DISC1 protein bands seen by Western blotting. Further studies of both mRNA and protein are needed. In addition, we need to pay attention to posttranslational modifications and their contribution to the complexity of DISC1 signals in Western blotting. Taking all this together we propose the following criteria for all future DISC1 research: (1) when we use animal models for DISC1, the use of the C57BL/6 strain without the 25-base deletion is strongly recommended; (2) to detect DISC1 protein in brain samples, reliable pairs of antibodies against DISC1 should be used in immunoprecipitation-Westerns (one antibody is used for immunoprecipitation and the other for Western blotting), leading to enhanced DISC1 signals in the immunoprecipitates; and (3) use of multiple RNAi targeting constructs to different regions of DISC1 is recommended. The design of these constructs should take into consideration the different DISC1 isoforms, and be combined with a rescue experiment by co-expressing a known DISC1 isoform, such as full-length isoform L. Through these experiments, we can be confident that functions of DISC1 revealed by RNAi experiments are at least associated with known isoforms.
Second, some unanswered questions on the molecular nature of DISC1 may be clarified with novel cell engineering technology, which generates induced pluripotent stem cells (iPS cells) and induced neural cells (iN cells). This technology allows us to generate neurons from peripheral tissues, such as skin fibroblasts, of patients and normal controls. This technology is being taken up rapidly and it is already being rewardrd across the psychiatric diseases, such as Rett syndrome and schizophrenia196. Although the implication of the genetic variant to psychiatric illnesses is unclear197,198, generation of iPS cells carrying a DISC1 frameshift mutation was recently reported199. In the future it will be interesting to establish iPS cells from the Scottish pedigree with the chromosomal translocation.
Third, although many possible functions for DISC1 have been suggested, functional validation in vivo has been sufficiently achieved only in the context of early development, such as corticogenesis and adult neurogenesis in the dentrate gyrus. Studies on synaptic DISC1 have involved functional validation in vivo, but assessment of real-time spine dynamics using multiphoton microscopy and impact on distinct circuitry by optogenetic approaches is awaited. In addition, DISC1 is expressed in both neurons and glial cells (astrocytes, oligodendrocytes, and microglia). Thus, the spatial and temporal specificity of DISC1 activity is a key outstanding point to address. So far, most of the studies have focused on DISC1 in progenitor cells and pyramidal neurons in the cortex and hippocampus. It is very important to address the significance of DISC1 in interneurons and glial cells. Minor isoforms that were reported in brain homogenates may reflect important isoforms in specific cell types. Thus, when we conduct functional assays, cell type-specific targeting is very important. Furthermore, brain development and function are determined by the interaction of genetic and environmental factors. Therefore, how environmental factors and stressors may influence DISC1 cascades during development and the overall brain function need to be further addressed.
Finally, although DISC1 has been established to be a key regulatory molecule in diverse processes of neurodevelopment and synaptic function, its translational potential may be different from the one originally expected under the name of “Disrupted-in-Schizophrenia.” As described above, the importance of DISC1 as a genetic risk factor is rather weak in schizophrenia, instead the molecular pathways involving DISC1 seems to be implicated in unique endophenotypes that underlie many distinct mental disorders labeled by current diagnostic manuals. Thus, DISC1 biology may possibly provide a hint on constructing new diagnostic criteria for mental disorders at a more biological (and likely relevant) basis. DISC1 animal models need to be further characterized, with a more thorough cross-lab, circuit-based approach. Then the phenotypes can be explained by the underlying circuit deficits, which should allow better correlation to the clinical data in patients. Lastly, we are optimistic that important drug targets will be identified from understanding the molecular pathways of DISC1, which will provide therapeutic advantages beyond current drugs across multiple mental illness diagnoses.
We thank Ms. Yukiko L. Lema for preparing figures and organizing the manuscript and Prof. Douglas Blackwood for preparation of Box 1. We also thank Drs. Hanna Jaaro-Peled, Koko Ishizuka, and Minae Niwa for critical reading of the manuscript. Grant supports (A.S.): from MH-084018, MH-94268 Silvo O. Conte center, MH-069853, MH-085226, MH-088753, MH-092443, Stanley, RUSK, S-R foundations, NARSAD and Maryland Stem Cell Research Fund.
Nick Brandon leads research efforts into Psychiatry and Behavioral Disorders at Pfizer Neuroscience. Nick was educated at the University of Cambridge and University College London and then worked at Merck and Wyeth. His lab is focused on identifying therapeutic strategies to treat mental illness, including schizophrenia and autism.
Akira Sawa is Director of the Johns Hopkins Schizophrenia Center and Professor, Departments of Psychiatry and Neuroscience. Akira started his career as a psychiatrist and later conducted postdoctoral research training under Solomon Snyder. Since 2001, Akira has served as faculty at Johns Hopkins University.